SK Chemicals’ hemophilia treatment, AFSTYLA, approved by EMA
SK Chemicals(CEO Man-Hoon Park) announced, on the 10th, the hemophilia treatment ‘AFSTYLA’ acquired the final commercialization approval from the European Medicines Agency(EMA). Thus, AFSTYLA becomes the first drug entered in the EU as a biomedicine developed by Korean technology.
CSL has carrie...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
